Neuroleptic	neuroleptic	O	DISEASE	OTHERS	I
malignant	malignant	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
with	with	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Neuroleptic	neuroleptic	O	DISEASE	OTHERS	I
malignant	malignant	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
is	is	O	O	O	O
thought	thought	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
a	a	O	O	O	O
result	result	O	O	O	O
of	of	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
D2	d2	O	O	O	O
receptor	receptor	O	O	O	O
blockade	blockade	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
striatum	striatum	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
basal	basal	O	O	O	O
ganglia	ganglia	O	O	O	O
.	.	O	O	O	O

Risperidone	risperidone	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
benzisoxazole	benzisoxazole	O	O	OTHERS	I
derivative	derivative	O	O	O	O
antipsychotic	antipsychotic	O	O	O	O
,	,	O	O	O	O
has	has	O	O	O	O
high	high	O	O	O	O
serotonin	serotonin	CHEMICALS	O	OTHERS	I
5-HT2	5-ht2	O	O	OTHERS	I
receptor	receptor	O	O	O	O
blockade	blockade	O	O	O	O
and	and	O	O	O	O
dose-related	dose-related	O	O	O	O
D2	d2	O	O	O	O
receptor	receptor	O	O	O	O
blockade	blockade	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
high	high	O	O	O	O
ratio	ratio	O	O	O	O
is	is	O	O	O	O
believed	believed	O	O	O	O
to	to	O	O	O	O
impart	impart	O	O	O	O
the	the	O	O	O	O
low	low	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
extrapyramidal	extrapyramidal	O	DISEASE	OTHERS	I
symptoms	symptoms	O	DISEASE	OTHERS	I
with	with	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
low	low	O	O	O	O
dosages	dosages	O	O	O	O
.	.	O	O	O	O

With	with	O	O	O	O
this	this	O	O	O	O
low	low	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
extrapyramidal	extrapyramidal	O	DISEASE	OTHERS	I
symptoms	symptoms	O	DISEASE	OTHERS	I
,	,	O	O	O	O
it	it	O	O	O	O
was	was	O	O	O	O
thought	thought	O	O	O	O
the	the	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
neuroleptic	neuroleptic	O	DISEASE	OTHERS	I
malignant	malignant	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
might	might	O	O	O	O
also	also	O	O	O	O
be	be	O	O	O	O
lowered	lowered	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
73-year-old	73-year-old	O	O	O	O
woman	woman	O	O	O	O
developed	developed	O	O	O	O
neuroleptic	neuroleptic	O	DISEASE	OTHERS	I
malignant	malignant	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
after	after	O	O	O	O
monotherapy	monotherapy	O	O	O	O
with	with	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
syndrome	syndrome	O	O	O	O
reversed	reversed	O	O	O	O
after	after	O	O	O	O
discontinuing	discontinuing	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
starting	starting	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
dantrolene	dantrolene	O	O	OTHERS	I
and	and	O	O	O	O
bromocriptine	bromocriptine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

It	it	O	O	O	O
appears	appears	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
protection	protection	O	O	O	O
from	from	O	O	O	O
extrapyramidal	extrapyramidal	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
observed	observed	O	O	O	O
with	with	O	O	O	O
risperidone	risperidone	CHEMICALS	O	OTHERS	I
does	does	O	O	O	O
not	not	O	O	O	O
ensure	ensure	O	O	O	O
protection	protection	O	O	O	O
from	from	O	O	O	O
neuroleptic	neuroleptic	O	DISEASE	OTHERS	I
malignant	malignant	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

